Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Nantahala Capital Management

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 33
Average round size
info
The average size of a deal this fund participated in
$60M
Portfolio companies 29
Lead investments 3
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.12
Exits 25
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Nantahala Capital Management:
Typical Co-investors
Nantahala Capital Management is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Nantahala Capital Management:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Access Ventures China, Hong Kong, Hong Kong Island
American Underground Durham, North Carolina, United States
Aspen Grove Capital Avon, Colorado, United States
BackBone Ventures Switzerland, Zurich, Zurich
Dynegy Houston, Texas, United States
Fast Forward California, San Francisco, United States
Government of Slovak Republic District of Zvolen, Region of Banská Bystrica, Slovakia
Hyundai Mobis Seoul, Seoul-t'ukpyolsi, South Korea
LendingTree Charlotte, North Carolina, United States
Macanta Investments -
Montlake Capital Seattle, United States, Washington
Rebright Partners Chiyoda, Japan
Rhythm VC New York, New York, United States
SamInvest Mitt Härnösands domkyrkodistrikt, Sweden, Västernorrland County
Shenzhen Baodechang Investment China, Guangdong, Shenzhen
South Valley Angels California, Morgan Hill, United States
The Capital Partnership England, London, United Kingdom
Topline Capital California, United States, Villa Park
W.R. Huff Asset Management Co. LLC. Florida, Stuart, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Disc Medicine

Biotechnology
Health Care
Medical
$90M02 Sep 2021 Cambridge, Massachusetts, United States

Silverback Therapeutics

Biopharma
Biotechnology
Health Care
Medical
Therapeutics
$85M23 Sep 2020 Seattle, Washington, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Nantahala Capital Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 33
Average round size 60M
Peak activity year 2024
Lead investments 3
Follow on index 0.12
Exits 25
Group Appearance index 0.97

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Disc Medicine

Biotechnology
Health Care
Medical
$90M02 Sep 2021 Cambridge, Massachusetts, United States

Silverback Therapeutics

Biopharma
Biotechnology
Health Care
Medical
Therapeutics
$85M23 Sep 2020 Seattle, Washington, United States
Crunchbase icon

Content report

The following text will be sent to our editors: